African Patients and Trialists Largely Left Out of CV Research

Why It Matters

Excluding Africa compromises the accuracy of global cardiovascular guidelines and drug safety data, jeopardizing health outcomes for a quarter of the world’s population. Addressing this gap is essential for truly evidence‑based medicine and equitable health innovation.

Key Takeaways

• <4% of 2,472 RCTs were Africa‑only; cardiology <1%
• African lead authors appear in only 3.6% of multinational trials
• Excluding Africa risks inaccurate drug safety data for 25% world
• Funding models need African co‑leadership, ring‑fenced resources
• Journals urged to require diversity reporting and justification

Pulse Analysis

The stark underrepresentation of African cohorts in cardiovascular research undermines the scientific foundation of global guidelines. While Africa accounts for roughly 25 % of the world’s population and carries a growing burden of heart disease, only 0.6 % of randomized trials in leading cardiology journals involve exclusively African sites. This paucity means that disease phenotypes unique to the continent—such as higher rates of rheumatic heart disease, hypertension, and co‑existing infections—are rarely reflected in the evidence that shapes treatment protocols worldwide. Consequently, clinicians may rely on data that do not capture regional genetic, environmental, or socioeconomic factors, leading to suboptimal care.

Funding structures and governance models are at the heart of this disparity. Most multinational trials are designed and led by high‑income institutions, with African investigators appearing as senior authors in merely 3.6 % of such studies. Without equitable co‑leadership, African researchers lack control over protocol design, data ownership, and publication credit. Moreover, the absence of dedicated, ring‑fenced resources hampers the development of local trial infrastructure, biorepositories, and data systems needed for sustainable research capacity. Incorporating African scientists as decision‑makers from conception through execution can improve trial relevance, enhance safety monitoring—especially given evidence of three‑ to‑fourfold higher adverse drug reactions in African patients—and foster trust within local communities.

To close the gap, journals, funders, and professional societies must adopt concrete policies. Editorial boards should mandate reporting of population diversity and require scientific justification when African cohorts are omitted from high‑burden disease trials. Funding agencies need to allocate protected budgets for African‑led projects and invest in regional trial networks, training pipelines, and shared registries. By embedding Africa into guideline‑development processes and hosting major conferences on the continent, the global research ecosystem can move from awareness to accountability, ensuring that evidence‑based medicine truly reflects the whole world.